Hong Kong stock movement: 160 HEALTH falls over 10%, market volatility intensifies, capital flow attracts attention

Hong Kong Stock Movement 160 HEALTH, down 10.63%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked High in Industry Transaction Volume China National Pharmaceutical Group, down 0.11%. Based on recent key news: On May 9, China National Pharmaceutical Group and Bichang Pharmaceutical reached a strategic signing in Xi'an, deciding to further deepen all-round strategic cooperation. This move aims to promote systematic upgrades from channel optimization to innovative drug commercialization, from logistics collaboration to full-scenario health services, jointly creating a benchmark model for compliant operation and collaborative development in the pharmaceutical industry. This news may have a positive impact on the stock price, but the market reaction in the short term is limited. No other significant news recently. The trend of cooperation in the pharmaceutical industry is strengthening, with attention to policy changes. Shanghai Pharmaceuticals, up 0.41%. Based on recent key news: On May 8, Shanghai Pharmaceuticals' major shareholder, Shanghai Industrial Group, increased its shareholding from 38.03% to 39%. This move was completed through concentrated bidding transactions in the secondary market, funded by self-owned capital, enhancing market confidence in the company's future development and driving the stock price up. On May 8, the rivaroxaban tablets produced by Changzhou Pharmaceutical Factory, a subsidiary of Shanghai Pharmaceuticals, were approved for listing in Thailand. This drug is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and is expected to increase the company's sales in the Southeast Asian market, further boosting the stock price. On May 8, IQVIA data showed that the total sales of rivaroxaban tablets in the Thai market last year amounted to USD 18.72 million. Shanghai Pharmaceuticals' R&D investment in the Southeast Asian market is approximately RMB 3.2482 million, demonstrating the company's positive momentum in expanding into international markets, supporting the stock price increase. The pharmaceutical industry is supported by policies, and the market is active. Yunnan Baiyao, up 0.36%, with a transaction volume reaching HKD 31.46 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked High in Industry Market Capitalization GUANZE MEDICAL, down 9.65%. Based on recent key news: On May 8, GUANZE MEDICAL completed shareholder cash settlement, stabilizing the holding structure. The final settlement of this transaction marks the stability of the company's holding structure. Although technical sentiment signals indicate buying, the stock price still fell by 9.65%. On May 8, GUANZE MEDICAL's operations in the medical information service sector failed to boost the stock price. The company focuses on medical information services, providing data and related solutions, but the market response was poor, leading to a decline in the stock price. On May 8, the market's response to GUANZE MEDICAL's trading volume and technical signals was lukewarm. Despite an average trading volume of 5,552,367 and technical signals indicating buying, the stock price still fell. The medical information industry has recently shown weak performance